本季度信息
TATA健康（01255）公告显示，截至2024年6月30日止六个月，公司实现营收约0.72亿港元，同比上一年同期的1.04亿港元下滑30.6%。同期毛利率为76.6%，较上一年同期的81.9%有所下降。经营活动所产生的现金流由上一年同期的流入474.4万港元转为本期流出1,404.2万港元。
成本结构方面，销售及分销成本总额同比减少约33.8%，管理费用同比减少约49.3%，整体费用水平出现明显下行。
业务分项
鞋类业务是主要收入来源，报告期实现收入0.72亿港元，同比减少28.2%。受市场环境与消费情绪等因素影响，其余业务板块规模较小，保健业务与线上医疗服务在报告期内均无收入进账，金融服务收入也为零。
高管解读 （本期公告中无直接引用的高管发言，故此部分无内容）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.